Nektar falls on TNBC data for doublet, but considering moving ahead with a triple combo

Despite shedding over $200 million from its market cap Thursday after reporting response data from the triple-negative breast cancer cohort of its bempegaldesleukin/Opdivo nivolumab combination trial, Nektar is looking ahead to the next set of trials for the combo.

In the Phase I/II PIVOT-02

Read the full 446 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE